Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158


[Chromosome arm 17p13.3: could HIC1 be the one ?].

Chopin V, Leprince D.

Med Sci (Paris). 2006 Jan;22(1):54-61. Review. French.


Inactivation of the hypermethylated in cancer 1 tumour suppressor--not just a question of promoter hypermethylation?

Jenal M, Britschgi C, Fey MF, Tschan MP.

Swiss Med Wkly. 2010 Nov 1;140:w13106. doi: 10.4414/smw.2010.13106. Review.


A L225A substitution in the human tumour suppressor HIC1 abolishes its interaction with the corepressor CtBP.

Stankovic-Valentin N, Verger A, Deltour-Balerdi S, Quinlan KG, Crossley M, Leprince D.

FEBS J. 2006 Jul;273(13):2879-90. Epub 2006 Jun 7.


Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma.

Stöcklein H, Smardova J, Macak J, Katzenberger T, Höller S, Wessendorf S, Hutter G, Dreyling M, Haralambieva E, Mäder U, Müller-Hermelink HK, Rosenwald A, Ott G, Kalla J.

Oncogene. 2008 Apr 17;27(18):2613-25. Epub 2007 Nov 5.


Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1.

Britschgi C, Rizzi M, Grob TJ, Tschan MP, Hügli B, Reddy VA, Andres AC, Torbett BE, Tobler A, Fey MF.

Oncogene. 2006 Mar 30;25(14):2030-9.


HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.

Fleuriel C, Touka M, Boulay G, Guérardel C, Rood BR, Leprince D.

Int J Biochem Cell Biol. 2009 Jan;41(1):26-33. doi: 10.1016/j.biocel.2008.05.028. Epub 2008 Aug 3. Review.


Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.

Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB.

Cancer Cell. 2004 Oct;6(4):387-98.


An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity.

Stankovic-Valentin N, Deltour S, Seeler J, Pinte S, Vergoten G, Guérardel C, Dejean A, Leprince D.

Mol Cell Biol. 2007 Apr;27(7):2661-75. Epub 2007 Feb 5.


Isolation and embryonic expression of the novel mouse gene Hic1, the homologue of HIC1, a candidate gene for the Miller-Dieker syndrome.

Grimm C, Spörle R, Schmid TE, Adler ID, Adamski J, Schughart K, Graw J.

Hum Mol Genet. 1999 Apr;8(4):697-710.


Characterization of HRG22, a human homologue of the putative tumor suppressor gene HIC1.

Deltour S, Pinte S, Guérardel C, Leprince D.

Biochem Biophys Res Commun. 2001 Sep 21;287(2):427-34.


Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses.

Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB.

Cell. 2005 Nov 4;123(3):437-48.


Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers.

Konishi H, Takahashi T, Kozaki K, Yatabe Y, Mitsudomi T, Fujii Y, Sugiura T, Matsuda H, Takahashi T, Takahashi T.

Oncogene. 1998 Oct 22;17(16):2095-100.


Implication of HIC1 (Hypermethylated In Cancer 1) in the DNA damage response.

Dehennaut V, Leprince D.

Bull Cancer. 2009 Nov;96(11):E66-72. doi: 10.1684/bdc.2009.0959. Review.


Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.

Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Børresen AL, Cornelisse CJ, Devilee P.

Cancer Res. 1994 Aug 1;54(15):4200-6.


p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.

Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB.

Nat Med. 1995 Jun;1(6):570-7.


Physical and transcriptional mapping of the 17p13.3 region that is frequently deleted in human cancer.

Hoff C, Seranski P, Mollenhauer J, Korn B, Detzel T, Reinhardt R, Ramser J, Poustka A.

Genomics. 2000 Nov 15;70(1):26-33.


Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors.

Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB.

Nat Genet. 2003 Feb;33(2):197-202. Epub 2003 Jan 21.


Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas.

Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, Vives J, Cardesa A, Yague J.

Cancer. 1994 Jun 15;73(12):2913-21.

Supplemental Content

Support Center